Avalon GloboCare (ALBT) Competitors $2.24 -0.02 (-0.88%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$2.24 +0.00 (+0.18%) As of 10/17/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALBT vs. RANI, PLUR, SONN, TENX, PYRGF, AKTX, IMA, GLTO, SCYX, and PMNShould you be buying Avalon GloboCare stock or one of its competitors? The main competitors of Avalon GloboCare include Rani Therapeutics (RANI), Pluri (PLUR), Sonnet BioTherapeutics (SONN), Tenax Therapeutics (TENX), PyroGenesis Canada (PYRGF), Akari Therapeutics (AKTX), ImageneBio (IMA), Galecto (GLTO), SCYNEXIS (SCYX), and Promis Neurosciences (PMN). These companies are all part of the "pharmaceutical products" industry. Avalon GloboCare vs. Its Competitors Rani Therapeutics Pluri Sonnet BioTherapeutics Tenax Therapeutics PyroGenesis Canada Akari Therapeutics ImageneBio Galecto SCYNEXIS Promis Neurosciences Avalon GloboCare (NASDAQ:ALBT) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations. Is ALBT or RANI more profitable? Rani Therapeutics has a net margin of 0.00% compared to Avalon GloboCare's net margin of -1,451.94%. Avalon GloboCare's return on equity of 0.00% beat Rani Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avalon GloboCare-1,451.94% N/A -75.12% Rani Therapeutics N/A -1,258.76%-97.97% Which has better valuation and earnings, ALBT or RANI? Avalon GloboCare has higher revenue and earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvalon GloboCare$1.33M6.47-$7.90M-$19.96-0.11Rani Therapeutics$1.03M114.43-$30.02M-$0.91-1.80 Which has more volatility and risk, ALBT or RANI? Avalon GloboCare has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of -0.02, indicating that its share price is 102% less volatile than the S&P 500. Does the media prefer ALBT or RANI? In the previous week, Rani Therapeutics had 18 more articles in the media than Avalon GloboCare. MarketBeat recorded 18 mentions for Rani Therapeutics and 0 mentions for Avalon GloboCare. Rani Therapeutics' average media sentiment score of 0.14 beat Avalon GloboCare's score of 0.00 indicating that Rani Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Avalon GloboCare Neutral Rani Therapeutics Neutral Do analysts rate ALBT or RANI? Rani Therapeutics has a consensus target price of $7.33, suggesting a potential upside of 347.15%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rani Therapeutics is more favorable than Avalon GloboCare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalon GloboCare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Rani Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do institutionals and insiders have more ownership in ALBT or RANI? 1.4% of Avalon GloboCare shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 37.3% of Avalon GloboCare shares are held by company insiders. Comparatively, 45.1% of Rani Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryRani Therapeutics beats Avalon GloboCare on 10 of the 16 factors compared between the two stocks. Get Avalon GloboCare News Delivered to You Automatically Sign up to receive the latest news and ratings for ALBT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALBT vs. The Competition Export to ExcelMetricAvalon GloboCareMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.59M$3.44B$6.19B$10.55BDividend YieldN/A2.28%5.70%4.81%P/E Ratio-0.1123.1685.6227.13Price / Sales6.47499.63615.49134.47Price / CashN/A46.9237.1060.81Price / Book-0.2010.4112.236.52Net Income-$7.90M-$52.77M$3.33B$276.93M7 Day Performance-0.88%2.31%1.17%1.93%1 Month Performance-16.73%12.59%6.85%2.19%1 Year Performance-17.04%11.18%58.93%34.62% Avalon GloboCare Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALBTAvalon GloboCare0.9022 of 5 stars$2.24-0.9%N/A-17.0%$8.59M$1.33M-0.115RANIRani Therapeutics2.5916 of 5 stars$0.49-2.5%$7.33+1,387.5%-38.8%$35.43M$1.03M-0.54110Trending NewsShort Interest ↑Gap UpPLURPluri2.4297 of 5 stars$4.32+0.1%$12.00+178.1%-10.6%$35.21M$1.34M-0.83150News CoverageGap DownSONNSonnet BioTherapeutics1.71 of 5 stars$5.14-5.6%$20.00+289.5%-41.9%$35.07M$1M0.0010News CoverageTENXTenax Therapeutics1.857 of 5 stars$7.56-1.3%$18.00+138.1%+69.1%$34.47MN/A-8.229News CoverageAnalyst ForecastShort Interest ↑PYRGFPyroGenesis Canada0.5269 of 5 stars$0.18-2.9%N/A-67.0%$34.04M$9.14M-3.0390News CoverageAKTXAkari Therapeutics2.6406 of 5 stars$1.04+1.0%$3.30+218.8%-66.2%$33.76MN/A0.009News CoverageShort Interest ↑Gap UpIMAImageneBio2.8573 of 5 stars$8.30-3.6%$35.50+327.7%-63.3%$33.28M$9.16M-1.0870Negative NewsShort Interest ↑GLTOGalecto0.6561 of 5 stars$25.03+574.7%$10.00-60.0%+34.6%$33.04MN/A-1.9140Analyst ForecastShort Interest ↑Gap DownHigh Trading VolumeSCYXSCYNEXIS0.6895 of 5 stars$0.78-0.7%N/A-52.8%$32.82M$3.75M-1.9660News CoverageAnalyst ForecastShort Interest ↑Gap DownPMNPromis Neurosciences3.7124 of 5 stars$0.57+3.0%$4.33+667.0%-55.8%$30.40MN/A-2.695Short Interest ↓Gap Down Related Companies and Tools Related Companies Rani Therapeutics Competitors Pluri Competitors Sonnet BioTherapeutics Competitors Tenax Therapeutics Competitors PyroGenesis Canada Competitors Akari Therapeutics Competitors ImageneBio Competitors Galecto Competitors SCYNEXIS Competitors Promis Neurosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALBT) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalon GloboCare Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalon GloboCare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALBT Stock Alerts